Guardant Health Raises $50M in Series C to Expand Reach of Cancer Blood Test, Speed up Development | GenomeWeb

NEW YORK (GenomeWeb) – Guardant Health has raised $50 million in a Series C financing round, the company said today.

The financing, which was led by Lightspeed Venture Partners, with Formation 8 and existing investors Khosla Ventures and Sequoia Capital participating, brings the company's total funding to date to just under $100 million. The company raised $30 million in a Series B round last April.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.